[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seoul National University Boramae Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100225016",false,"NCT02206841","Establishment of NAFLD Cohort and Development of Fibrosis Markers","Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis","NAFLD","Inclusion Criteria:\n\n* Patients with histologically confirmed fatty liver disease\n* Patients with radiologically confirmed fatty liver disease\n\nExclusion Criteria:\n\n* History of significant alcohol consumption\n* Viral hepatitis\n* Autoimmune hepatitis\n* Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)\n* Hepatotoxic medication (e.g. amiodarone)","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","3 Years","OBSERVATIONAL","This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.",[25],"Fibrosis of Liver",[27,28],"fibrosis","markers","RECRUITING","2025-05-12",{"date":32,"type":33},"2025-05-15","ACTUAL",{"date":35,"type":4},"2014-01-01",{"date":37,"type":20},"2030-12-31",{"name":39,"class":40},"Seoul National University Boramae Hospital","OTHER",""]